Patents by Inventor Amy Rayo

Amy Rayo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250223359
    Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19 including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
    Type: Application
    Filed: November 12, 2024
    Publication date: July 10, 2025
    Applicant: Novartis AG
    Inventors: Brian Granda, Amy Rayo, Connie Hong, Dattananda Chelur, Haihui Lu, Regis Cebe, Sunyoung Jang
  • Publication number: 20250215081
    Abstract: The present disclosure provides combinations of anti-CD19 agents and B cell targeting agents and methods of treating subjects having B cell malignancies with combinations of anti-CD19 agents and a B cell targeting agents.
    Type: Application
    Filed: November 4, 2021
    Publication date: July 3, 2025
    Inventors: Kimberly Marie AARDALEN, Regis CEBE, Dattananda CHELUR, Glenn DRANOFF, Brian Walter GRANDA, Nadia HASSOUNAH, Connie HONG, Sunyoung JANG, Haihui LU, Amy RAYO, Darko SKEGRO, Janghee WOO
  • Patent number: 12221481
    Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: February 11, 2025
    Assignee: Novartis AG
    Inventors: Brian Granda, Amy Rayo, Connie Hong, Dattananda Chelur, Haihui Lu, Regis Cebe, Sunyoung Jang
  • Publication number: 20250000973
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: August 19, 2022
    Publication date: January 2, 2025
    Inventors: Michael Bardroff, Regis Cebe, Brian Walter Granda, Shyamali Jayashankar, Sandeep Tharian Koshy, Sandra Miller, Andrew Patrick Price, Amy Rayo, Darko Skegro, Louise Mary Treanor, Jennifer Yang
  • Publication number: 20240025993
    Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 25, 2024
    Inventors: Regis CEBE, Dattananda CHELUR, Brian Walter GRANDA, Connie WONG, Sunyoung JANG, Haihui LU, Amy RAYO, Darko SKEGRO
  • Publication number: 20230302155
    Abstract: Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.
    Type: Application
    Filed: August 20, 2021
    Publication date: September 28, 2023
    Inventors: Sandeep Tharian Koshy, Glenn Dranoff, Maria Anna Sofia Broggi, Chris Bridgeman, Stephen Michael Canham, Yoel Melles, Regis Cebe, Brian Walter Granda, Louise Mary Treanor, Shyamali Jayashankar, Jennifer Yang, Amy Rayo, Andrew Patrick Price, Darko Skegro, Justine Guyot, Tushar Dattu Apsunde, Cameron Chuck-munn Lee, Michael Bardroff, Sandra Miller
  • Publication number: 20230256017
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 17, 2023
    Inventors: Jennifer BROGDON, Glenn DRANOFF, Michael R. GREENE, Anniesha HACK, Olja KODRASI, Elizabeth Dorothy PRATICO, Andrew PRICE, Andrew Marc STEIN, Amy RAYO, Jennifer YANG, Brian Walter GRANDA, Attilio BONDANZA, Boris ENGELS, Hyungwook LIM, Akash SOHONI, Louise TREANOR, Xu ZHU, Carla GUIMARAES, Shyamali JAYASHANKAR, Sandeep Tharian KOSHY, Regis CEBE, Michael BARDROFF, Sandra MILLER
  • Publication number: 20230037682
    Abstract: Provided are CD3 binding molecules that specifically bind to CD3, for example monospecific binding molecules that specifically bind to CD3 and multispecific binding molecules (MBMs) that specifically bind to CD3 and a tumor-associated antigen, conjugates comprising the CD3 binding molecules, and pharmaceutical compositions comprising the CD3 binding molecules and conjugates. Provided are methods of using the CD3 binding molecules, conjugates, and pharmaceutical compositions to activate T cells in a subject, for example a subject having a cancer or autoimmune disease. Provided are recombinant host cells engineered to express the CD3 binding molecules and methods of producing the CD3 binding molecules by culturing the host cells under conditions in which the CD3 binding molecules are expressed.
    Type: Application
    Filed: December 4, 2019
    Publication date: February 9, 2023
    Inventors: Brian Walter GRANDA, Daniel LENHERR-FREY, Xuerui LUO, Amy RAYO, Fei ZHANG, Jiquan ZHANG
  • Publication number: 20210139585
    Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
    Type: Application
    Filed: May 19, 2020
    Publication date: May 13, 2021
    Applicant: Novartis AG
    Inventors: Brian Granda, Amy Rayo, Connie Hong, Dattananda Chelur, Haihui Lu, Regis Cebe, Sunyoung Jang